Clinical Trial Update: High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating high-dose I-131 MIBG for metastatic neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• I-131 Metaiodobenzylguanidine (metaiodobenzylguanidine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Neuroendocrine Tumors, Metastases, Neoplasm | Phase 3 | Status: COMPLETED